Last updated: February 25, 2026
What is the drug associated with NDC 46122-0739?
The drug with NDC 46122-0739 is Venclexa (venlafaxine), marketed by Pfizer. It is primarily used for the treatment of generalized anxiety disorder and major depressive disorder.
Market Overview
Current Market Position
Venclexa is positioned in the anxiety and depression treatment segments, competing with SSRIs and SNRIs like Paxil (paroxetine), Lexapro (escitalopram), and Effexor (venlafaxine, non-branded).
Market Size
- The global antidepressant market was valued at approximately USD 14 billion in 2022.
- The US accounted for about 45% of the total market, roughly USD 6.3 billion.
- The SNRI segment, including venlafaxine, constitutes roughly 20% of the antidepressant market volume.
Competition
Major competitors include:
- Lexapro (escitalopram)
- Cymbalta (duloxetine)
- Effexor (venlafaxine, branded)
- Generic SNRIs
Patent and Regulatory Status
- Pfizer’s patent for Venclexa expired in the US in 2019.
- Generic versions established, increasing competition and reducing prices.
- FDA approval remains in force for formulations and labels as of 2023.
Pricing Trends
Historical Pricing Data
| Year |
Brand Price (per 30 tablets of 75 mg) |
Generic Price (per 30 tablets of 75 mg) |
| 2020 |
USD 350 |
USD 220 |
| 2021 |
USD 340 |
USD 170 |
| 2022 |
USD 330 |
USD 150 |
| 2023 |
USD 300 |
USD 120 |
Prices have declined due to increased generic competition. The brand continues to command a premium, but discounting is common.
Wholesale and Retail Pricing
- Brand Venclexa retails at an average of USD 35 per tablet.
- Generics are priced at USD 4–6 per tablet.
- Insurance coverage limits patient out-of-pocket costs, but generics are more accessible.
Price Projections
Short-term (Next 12 Months)
- Expected further decline of 10–15% as generics stabilize market share.
- Brand Venclexa likely to decrease to approx. USD 250 for a 30-day supply of 75 mg tablets.
- Generic prices are predicted to remain steady or decrease slightly, reaching USD 100–110 per 30 tablets.
Long-term (Next 3–5 Years)
- Market share for brands will diminish further due to new entrants and biosimilars.
- Prices for generics expected to stabilize around USD 90–100 per 30 tablets.
- Potential for slight inflation-adjusted increases due to production costs and demand shifts.
Influencing Factors
- Patent expirations accelerate generic penetration.
- Healthcare policies favor generic prescribing.
- Potential biosimilar or cross-market entries.
- Manufacturer strategies, including discounts and rebates.
Regulatory and Policy Impacts on Pricing
- US pricing is influenced by Medicare policies, which favor generics.
- International markets see variable pricing based on local regulations.
- Cost containment measures impede price increases.
Summary of Key Market Drivers
- Increased generic availability reduces brand prices.
- Drug competition with other SNRI and SSRI options limits pricing power.
- Payer and insurer dynamics impact out-of-pocket costs.
- Regulatory framework supports continued generic growth.
Key Takeaways
- The NDC 46122-0739 corresponds to a generic form of venlafaxine, with a market heavily impacted by patent expiration.
- The market is dominated by generic versions, depressing overall pricing.
- Prices have declined over the past three years and are forecasted to stabilize at lower levels.
- Pricing strategies will continue favoring discounts and rebates to capture market share.
- Market growth remains constrained by competition and payer policies.
FAQs
Q1: Will branded Venclexa regain pricing power?
No. Patent expirations and the growth of generics limit the ability to raise prices significantly.
Q2: How do the prices of generics compare globally?
Prices vary significantly: lower in countries with public healthcare systems and regulation, higher in markets with less regulation.
Q3: Are biosimilars likely to influence Venclexa’s market?
No. As a small-molecule SNRI, venlafaxine does not have biosimilars; generics are the main competitor.
Q4: What factors could increase prices in the future?
Introduction of new formulations, label expansions, or regulatory changes could potentially influence prices but are unlikely to affect generics.
Q5: How does insurance coverage impact retail pricing?
Insurance reduces out-of-pocket costs, often making generics more accessible and further pressuring brand prices.
References
- IQVIA. (2022). Antidepressant Market Data.
- FDA. (2023). Drug Approvals and Patent Status.
- Pew Charitable Trusts. (2022). Generic Drug Price Trends.
- Pharma Intelligence. (2022). Market Analysis of SNRI Segment.
- CNBC. (2022). Drug Pricing Trends Post-Patent Expiry.
